secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001437749-22-029261
Event type: litigation
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma settles Neratinib patent litigation with Sandoz; generic entry allowed Dec 2030
--------------------------------------------------------------------------------

- Settlement and License Agreement with Sandoz fully resolves pending Hatch-Waxman litigation in New Jersey.
- Sandoz receives a non-exclusive, royalty-free sublicense to key patents, including U.S. Patent No. 7,399,865 B2.
- Sandoz may begin selling generic Neratinib on or about December 8, 2030, subject to adjustment.
- Company and Wyeth also grant Sandoz a waiver of all regulatory exclusivities.
- Settlement eliminates burden, expense, and uncertainties of further litigation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922029261/0001437749-22-029261-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922029261/pbyi20221216_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-029261

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer